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Abstract Breast cancer is the most common female
cancer and is associated with a significant clinical and
economic burden. Multigene assays and molecular markers
represent an opportunity to direct chemotherapy only to
patients likely to have significant benefit. This systematic
review examines published health economic analyses to
assess the support for adjuvant therapy decision making.
Literature searches of PubMed, the Cochrane Library, and
congress databases were carried out to identify economic
evaluations of multigene assays and molecular markers
published between 2002 and 2012. After screening and
data extraction, study quality was assessed using the
Quality of Health Economic Studies instrument. The
review identified 29 publications that reported evaluations
of two assays: Oncotype DX and MammaPrint. Studies of
both tests provided evidence that their routine use was cost
saving or cost-effective versus conventional approaches.
Benefits were driven by optimal allocation of adjuvant
chemotherapy and reduction in chemotherapy utilization.
Findings were sensitive to variation in the frequency of
chemotherapy prescription, chemotherapy costs, and
patients’ risk profiles. Evidence suggests that multigene
assays are likely cost saving or cost-effective relative to
current approaches to adjuvant therapy. They should ben-
efit decision making in early-stage breast cancer in a
variety of settings worldwide.
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Abbreviations
ER Estrogen receptor
HTA Health Technology Assessment
LN Lymph node
MeSH Medical subject heading
MGA Multigene assay
NCCN National Comprehensive Cancer Network
NICE National Institute for Health and Clinical Excellence
NIH National Institutes of Health
QALE Quality-adjusted life expectancy
QALY Quality-adjusted life year
QHES Quality of Health Economic Studies
QoL Quality of life
SABC San Antonio Breast Cancer
Introduction
Breast cancer places a substantial burden on healthcare pro-
viders and is associated with significant mortality and reduced
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quality of life (QoL) [1–5]. Currently, following curative-
intent, patients typically undergo adjuvant treatment
consisting of radiotherapy, systematic treatment (if the
tumor is sensitive), human-epidermal-growth-factor-receptor-
2 (HER2)-directed therapy (if HER2 is overexpressed), and
often chemotherapy. The aim is to avoid cancer recurrence and
improve overall survival. Clinicians face difficult decisions
when prescribing adjuvant therapy, particularly with regard to
chemotherapy, balancing the benefit in terms of reduced risk
of recurrence, and improved survival with the adverse effects
of treatment. Current guidelines recommend chemotherapy in
the majority of early-stage breast cancer patients.
Recent development of commercially available multi-
gene assays (MGAs) may represent an opportunity to
identify patients who will and will not benefit from che-
motherapy, and adapt prescriptions accordingly. MGAs
quantify the expression of genes associated with the
underlying tumor biology and long-term outcomes [6–8].
Assays have proved to be prognostic and there are data
supporting prediction of chemotherapy benefit [9, 10].
MGAs have been included in the major international
guidelines for adjuvant breast cancer treatment in recent
years [11–14]. This systematic review summarizes the
available evidence from health economic analyses on
MGAs and molecular markers in breast cancer.
Literature search
Articles evaluating the economic impact of commercially
available MGAs and protein expression profiling on pre-
scriptions of adjuvant systemic therapy in breast cancer
were identified via a literature search. The tests included
were technologies under consideration by NICE in a recent
scoping exercise (Oncotype DX, MammaPrint, Blueprint,
PAM50, Breast Cancer Index, Mammostrat, and NPI?)
[15, 16]. The target population was considered to be all
early-stage, nonmetastatic breast cancer patients who
underwent curative-intent surgery.
Literature search of PubMed and the Cochrane Library
used medical subject heading (MeSH) major topics and a
number of ‘‘title and abstract’’ searches combined with
Boolean operators, to identify economic evaluations of
molecular diagnostic tests published between 1/1/2002 and
1/7/2012 [17]. Hand searches of PubMed identified
recently published articles without assigned MeSH terms.
HTA authority websites of the UK, Canada, Australia, and
USA were searched for any reports containing economic
models pertinent to this review. Meeting presentations
between 2009 and 2012 were also searched (Appendix).
Citations were screened by title and abstract against
inclusion criteria to identify publications assessing the
cost-effectiveness or budget impact of prognostic MGAs
and molecular markers. Full text was obtained for publi-
cations not clearly classified by abstract review. From
included articles, data were extracted on the methodolog-
ical characteristics and results of the publications. Meth-
odological data included the country setting, year of
analysis, modeling approach, time horizon, population,
outcomes reported, and data sources used. Extracted results
data were clinical outcomes, cost outcomes, and cost-
effectiveness results. In addition, studies evaluating budget
impact were included, defined as the estimation of the
financial consequences of introducing new healthcare
interventions for a defined healthcare payer or system.
The validated [18, 19] Quality of Health Economic
Studies (QHES) instrument was used to evaluate the
quality of economic evaluations. The QHES instrument
consists of 16 criteria addressing methodological charac-
teristics and transparency of reporting, and against which
economic evaluations are compared.
Results
Study selection
From 572 unique articles, screening identified 14 publica-
tions assessing the economic impact of using MGAs to guide
adjuvant breast cancer therapy. Hand searching of PubMed
identified four additional articles that had not yet been
assigned MeSH terms and the congress database search
yielded 14 pertinent abstracts. Of these, two studies were
described in journal articles already identified and were
therefore excluded. One further article was excluded fol-
lowing full text review because no price for the genomic-
profiling test was included [20]. Consequently, the 29
studies reviewed here comprise 17 journal published
manuscripts and 12 abstracts (Fig. 1). Of the identified
studies, the majority compared a MGA with current practice,
either Adjuvant!, St. Gallen or NCCN guidelines. Oncotype
DX was the test most commonly evaluated, with 18 cost-
effectiveness analyses and four budget impact studies
comparing it with current practice [21–42]. Of the remaining
studies, four cost-effectiveness evaluations and one budget
impact study compared MammaPrint with current practice,
and two studies compared Oncotype DXwith MammaPrint
[43–49]. Table 1 provides a brief description of Oncotype
DX and MammaPrint, the two tests with identified pub-
lished economic literature for review.
Cost-effectiveness evaluations of Oncotype DX
versus usual care
A total of 18 studies were identified that evaluated the cost-
effectiveness of Oncotype DX versus current treatment in
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estrogen receptor positive (ER?), HER2- early breast
cancer (Table 2). Of the 18 cost-effectiveness studies
identified, four explicitly stated that they used the same
model structure developed by Hornberger et al. in the first
published cost-effectiveness evaluation on Oncotype DX
[21–23, 32, 33], while a further four used a similar modeling
approach [24–26, 34]. The model developed by Hornberger
et al. [21] utilized a decision tree approach to model which
adjuvant therapies patients received before and after
Oncotype DX testing. Outcomes were then simulated
based on data from landmark trials using a Markov model
consisting of four states; no recurrence, recurrence with no
metastatic progression, recurrence with metastatic progres-
sion, and death. The impact of chemotherapy (in terms of
reduced risk of distant recurrence, decreased QoL, and
increased costs) was estimated in the Markov model,
depending on the treatment allocated in the decision tree.
Conceptually, a similar approach was used in all of the
Oncotype DX cost-effectiveness modeling studies identi-
fied in this review (i.e., estimates of long-term outcomes in a
population with and without Oncotype DX testing).
The results of the published cost-effectiveness analyses
were broadly consistent across the countries investigated
(including Australia, Canada (n = 5), Hungary, Ireland
(n = 3), Israel, Japan (n = 2), Singapore (n = 2), UK
(n = 2), and USA (n = 6)), indicating that Oncotype DX
testing is likely to improve outcomes, reduce the proportion
of patients treated with chemotherapy, and be cost-effec-
tive from a healthcare payer perspective according to
commonly accepted cost-effectiveness thresholds. Results
were different in the USA where Oncotype DX not only
improved outcomes, but was also cost saving (i.e., domi-
nant to the current standard of care), an effect driven lar-
gely by the fact that chemotherapy is more frequently
recommended and more expensive in the USA. This was
reflected in the recent analysis by Hornberger et al. [32]
based on chemotherapy utilization data from a meta-anal-
ysis of decision impact studies, which suggested that
Oncotype DX guided decision making dominated che-
motherapy decision making based on NCCN guidelines.
Other studies based on real-life chemotherapy prescribing
rates have shown Oncotype DX to be cost-effective
Articles identified in literature search: 664
Unique articles for title and abstract review: 
572
Articles included for full text review: 14
Articles included: 18
Publications identified: 32
Final publications included: 29
Duplicates removed: 92
Articles excluded: 559
Articles identified by hand 
searching: 4
Abstracts identified from congress 
databases: 14
Abstracts also published as 
journal articles: 2
Articles rejected after full text 
review: 1
Fig. 1 CONSORT flow diagram of literature review
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Table 1 Description of interventions included in the review
Intervention Level of supporting clinical evidence Description, prognostic and predictive ability
Oncotype DX 9 studies on analytical validation
8 publications describing clinical validation,
of which 7 studies provided evidence on the
prognostic ability, 1 study provided data on
predictive ability and 1 study provided results
on both
11 publications on decision impact studies
The assay evaluates the expression of a panel of 21 genes from a
tumor specimen (biopsy) using a high-throughput, real-time
reverse-transcriptase polymerase chain reaction (RT-PCR)
method to measure levels of gene expression. The gene
expression results from the assay are combined into a single score
called the Recurrence Score, which corresponds to a point
estimate of the 10-year risk of distant recurrence with a 95 %
confidence interval for an individual patient (expressed as a value
between 0 and 100).
Seven clinical trials have shown that Oncotype DX provides a
reliable evaluation of the risk of distant recurrence in early-stage
breast cancer patients. Studies have shown that low Recurrence
Score disease is associated with both a lower risk of distant
recurrence (as well as little (or no) chemotherapy benefit). From a
physician-patient perspective, the risk of distant recurrence
(based on the Recurrence Score) may directly influence
chemotherapy decision-making, with patients showing a high risk
of recurrence choosing adjuvant chemotherapy. For patients with
Recurrence Scores in the intermediate range (between 18 and
30), having a risk of recurrence in the upper end of the
intermediate range may lead to an increased interest in choosing
chemotherapy compared with having a risk of recurrence in the
lower end of the intermediate range.
The ability of Oncotype DX to predict the potential benefit of
adjuvant chemotherapy has been directly validated using two
prospectively designed studies of archived tumor specimens from
well-controlled clinical studies. These studies provide clear
evidence that patients with low Recurrence Scores derived
minimal, if any, benefit from chemotherapy in addition to
endocrine therapy and those with high Recurrence Scores had a
substantial benefit from the addition of chemotherapy to adjuvant
endocrine treatment. Further, data from two exploratory neo-
adjuvant trials where complete pathological responses (Gianni
et al. 2005) or complete clinical response (Chang et al. 2008)
have only been seen in patients with a Recurrence Score of 25 or
higher has emphasized the potential utility of the Recurrence
Score in predicting chemotherapy benefits
MammaPrint 6 publications describing analytical/clinical
validation, of which publication provided data
on prognostic ability (predictive ability is
assumed by association)
No decision impact studies were identified
The assay utilizes microarray technology to evaluate the expression
of a 70-gene panel, generated using RT-PCR, in fresh/frozen
tissue from test and reference samples. After normalization of
results, computer analysis is performed on the microarray results
of normal and diseased tissue can be compared to identify genes
that vary in their expression and also identify a pattern (profile)
that may indicate a distinct class or stage of disease. Based on
these results, patients are classified as at a high or low risk of
5-year distant recurrence.
One clinical study has provided evidence that the MammaPrint
gene signature has the ability to identify the likelihood of distant
recurrence in the first 5 years following diagnosis. Based on the
observation from the Early Breast Cancer Trialists’ Collaborative
Group, that adjuvant chemotherapy exerts its principal benefit in
reducing early metastasis risk during the first 5 years, it is
assumed that MammaPrint is predictive during the same interval
over which adjuvant chemotherapy exerts the maximum benefit.
Evidence regarding the prediction of benefits from chemotherapy
has not been independently demonstrated in randomized trials
Information on Oncotype DX was derived from the Manufacturer/Sponsor Submission of Evidence on the Oncotype DX Breast Cancer Test to NICE in
2011. Information on the MammaPrint test was taken from the product website (http://www.agendia.com/pages/mammaprint/21.php) accessed on August
16, 2012
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relative to usual care in four difference countries [26, 31,
34, 37]. In the published analyses, where costs have been
accounted from a societal perspective, Oncotype DX has
been found to be cost saving [25, 29].
Most evaluations were conducted in lymph node nega-
tive (LN-) patients (with long-term outcomes based on the
NSABP B-14 study [6]) but seven studies took into account
lymph node positive (LN?) patients (taking data from the
SWOG 8814 study [10]), either exclusively[30, 36, 37] or
in a mixed cohort [27, 31, 33, 37, 38]. The analyses suggest
that, while Oncotype DX may be more cost-effective in
LN- patients, it is also cost-effective in LN? patients and
cohorts containing a mixture of LN- and LN? patients.
Cost-effectiveness evaluations of MammaPrint
versus usual care
Four studies evaluated the cost-effectiveness of Mamma-
Print (Table 2) [43–46]. The 2010 article by Chen et al.
[44] reported that MammaPrint was likely to be cost-
effective in the overall population, highly cost-effective in
ER? patients, but associated with reduced survival and
quality-adjusted life expectancy (QALE) in patients with
estrogen receptor negative (ER-) disease in the USA.
These differences were driven by the proportion deter-
mined to be at high risk by the MammaPrint assay
(ER? 52 %, ER- 94 %). In the ER- group, MammaPrint
spared only 6 % of patients from receiving chemotherapy,
compared with 12 % in the ER? analysis. The fall in
chemotherapy usage in ER- patients led to reduced life
expectancy due to increased rates of distant recurrence
[50]. The authors noted that the results were very sensitive
to variation in clinical input data to the model (particularly
the proportion of patients with ER- disease), as well as
the cost of chemotherapy and the cost of MammaPrint.
Moreover, limited data on the predictive ability of the test
meant that it was assumed that the benefits of chemo-
therapy in both low-risk and high-risk patients were the
same.
Oestreicher et al. [43] reported negative outcomes
(decreased survival, decreased QALE, and lower costs) for
MammaPrint versus NIH clinical guidelines in a cost-
effectiveness evaluation in a mixed hypothetical population
of early-stage breast cancer patients in the US setting.
Poorer survival in the MammaPrint arm was driven by the
sensitivity of the test, modeled as 84 % in the base case
analysis. The authors stated that a sensitivity of 95 % is
required, with specificity maintained at the current value,
for MammaPrint to improve clinical outcomes. However,
the analysis is subject to several notable limitations,
including that the low risk/high assignation of patients
using MammaPrint was assumed based on other studies
(sensitivity and specificity estimates used to do this appear
low) and that the analysis failed to distinguish between
ER? and ER- patients.
In contrast, a more recent economic evaluation in the
Netherlands (Rete`l et al. [45]), showed improved survival
and quality-adjusted survival for MammaPrint over both
St. Gallen guidelines and Adjuvant!, and decreased costs
over an approach based on St. Gallen guidelines. The
analysis reported 20-year costs and outcomes for a hypo-
thetical cohort of patients with ER?, LN- disease, based
on a Markov model populated with sensitivity and speci-
ficity data derived from a pooled analysis of 305 tumor
samples from three previously reported validation studies
of MammaPrint. Benefits were driven by fewer patients
receiving unnecessary chemotherapy following Mamma-
Print testing compared with St. Gallen and Adjuvant!
approaches to adjuvant therapy decision making. Similar
findings were reported in the Japanese setting, where
Kondo et al. [46] investigated the cost-effectiveness of
MammaPrint versus St. Gallen criteria from a societal
perspective using an adaptation of a model previously used
to evaluate the cost-effectiveness of Oncotype DX. Pro-
jecting 10-year outcomes for a cohort of patients with
ER?, LN- disease, aged 55 years at baseline from a
Japanese cancer registry, MammaPrint was associated with
an improvement in QALE of 0.06 QALYs and an addi-
tional cost of JPY 231,385 per patient, leading to an ICER
of *JPY 3.9 million (USD 43,000) per QALY gained.
Results were sensitive to changing assumptions around risk
classification (low or high) and rates of distant recurrence.
Cost-effectiveness studies comparing Oncotype DX
and MammaPrint
Despite the lack of head-to-head clinical trial data or
decision impact studies, two studies directly compared the
cost-effectiveness of Oncotype DX with MammaPrint,
(Table 2) [48, 49]. Neither of these studies used the com-
mercially available assays, but instead assayed expression
of the same genes as in the commercial assays using their
own methodologies. The authors acknowledge that there is
significant uncertainty around the results and that the
analyses should be repeated in the future, using a mixed
treatment comparison approach or, ideally, data from a
head-to-head trial of the two gene expression-profiling
tests.
In the study by Yang et al. [49], MammaPrint was found
to dominate Oncotype DX, both in terms of improving
outcomes and reducing costs. There is, however, a lack of
transparency regarding outcome drivers because only the
final cost and QALE outcomes are reported. In the model,
instead of modeling the two tests directly against each
other, the two tests were individually compared with
Adjuvant! and then outcomes compared. Furthermore, the
632 Breast Cancer Res Treat (2013) 139:621–637
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cohorts used in the two analyses were neither the same nor
comparable. In the Oncotype DX versus Adjuvant! anal-
ysis, 47 % of patients were classified as high risk, while in
the MammaPrint versus Adjuvant! analysis, 74 % of
patients were considered at high risk. Therefore, one would
expect that more MammaPrint patients than Oncotype DX
patients would receive chemotherapy, and subsequently the
MammaPrint patients would accrue higher costs than
patients receiving Oncotype DX. The costs in the Mam-
maPrint arm are, though, unexpectedly lower [51]. More-
over, Oncotype DX patients with intermediate and high
Recurrence Scores were spuriously grouped together to
form a ‘‘high risk’’ group (as data suggests only around
50 % of intermediate Recurrence Score patients receive
chemotherapy). The noncomparable populations and the
lack of transparency make the results and validity of this
analysis difficult to interpret.
Rete`l et al. [48] used retrospective data from two analyses
of the sensitivity and specificity of a number of MGAs. In this
study, the outcome measured influenced the method deemed
most cost-effective. If the cost per QALY gained is the focus,
then MammaPrint was most cost-effective. Concentrating,
however, on the cost per life year gained, and Oncotype DX
has the highest probability of being cost-effective. Although
providing more readily comparable datasets than that used in
the Yang et al. study, a number of issues with this approach
remain. Firstly, one retrospective study was small, containing
only 26 tumor samples for assessment, taken from patients of
whom few had received tamoxifen [52]. Secondly, the larger
data set (295 samples) used data that was included in the
development of MammaPrint; thus, increasing the likelihood
that the MammaPrint predictions would be correct [53].
Budget impact studies
A total of four studies evaluated solely the budget impact of
Oncotype DX (as well as two that calculated both cost-
effectiveness and budget impact) and one evaluated the
budget impact of MammaPrint. The analysis by de Lima
Lopes et al. [29] used the model that was later used in the
2011 cost-effectiveness analysis by the same authors;[25];
however, clinical outcomes were not calculated in the first of
these studies. This study found that, on a per patient basis in
Singapore, Oncotype DX was cost saving, mainly driven
by reduced need for supportive care, and administration.
Analyses in Canada and the USA similarly found Oncotype
DX to be cost saving [40, 42], while two analyses in the
Irish setting reported approximate cost neutrality or cost
saving [39, 41]. An UK-based study found that Oncotype
DX was cost saving as long as over 40 % of the patients
tested were found to be at low risk [30]. The major driver of
cost savings in these budget impact analyses was the reduced
number of chemotherapy prescriptions. A similar result was
found in the budget impact study examining MammaPrint,
where cost savings were reported in the French setting [47].
The magnitude of reduction in chemotherapy prescriptions
in the budget impact analyses to date may be the key area of
differentiation from the published cost-effectiveness studies
(where chemotherapy sparing effects were more modest) in
which MGAs appear to be generally cost-effective (but cost
more than usual care). The only budget impact study in
which the gene expression-profiling test was found to
increase costs was a 2008 study of Oncotype DX in the
Japanese setting [23].
Evaluating study quality
The quality of the identified analyses was high. The mean
score for the studies comparing MGAs with current prac-
tice were both 86/100 for the Oncotype DX and Mam-
maPrint assays (Fig. 2). The most common area where
studies did not meet QHES criterion was explicit discus-
sion of bias (Appendix). A number of analyses also failed
to fully describe the model constructed and the assump-
tions used. These shortcomings, however, were relatively
minor and only five studies score \80/100.
The quality of the two studies comparing Oncotype
DX and MammaPrint was lower than those comparing
with usual care, scoring 66 and 72. These two studies
received lower ratings primarily as a result of the data
sources used to determine the treatment effects. One study
used randomized controlled trial evidence, but not from a
head-to-head study of the two interventions, and the other
used evidence from small retrospective studies, some of
which was used to inform creation of the MammaPrint test.


































vs. Onco type DX ®
studies
Fig. 2 Scatter plot of quality assessment of published, peer-reviewed
cost-effectiveness evaluations of Oncotype DX, and MammaPrint.
(The quality of studies supporting each gene expression test was
assessed using the Quality of Health Economic Studies (QHES)
instrument, generating a score out of 100, where higher scores reflect
higher quality. Each circle represents the QHES score from a single
study)
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patient groups was based on assumption. These studies also
received low scores as a result of limited sensitivity anal-
yses and lack of transparency, as very limited information
on the outcomes and drivers of outcomes were given.
Discussion
This review has collated the existing health economic
analyses examining the use of MGAs in guiding adjuvant
chemotherapy treatment in early-stage breast cancer. The
cost-effectiveness of only two assays, Oncotype DX and
MammaPrint, has been assessed in published literature.
The majority of the economic evaluations found that using
gene expression profiling to guide adjuvant therapy was
cost saving or cost-effective. This was the case for all
studies comparing Oncotype DX with current treatment
covering a range of populations with ER? early-stage
breast cancer across a number of different countries. The
cost-effectiveness profile of MammaPrint appears to be
more complex. Two studies support cost-effectiveness in
ER? populations, but in ER- patients and in a mixed
(ER?, ER-) population, the clinical outcomes were poorer
following MammaPrint testing than with usual care. Two
evaluations directly compared the cost-effectiveness of
MammaPrint with Oncotype DX. Both analyses found
MammaPrint to dominate Oncotype DX. Both, however,
are beset with methodological shortcomings and appear to
be at odds with the other published studies on the cost-
effectiveness of these gene-profiling tests. Budget impact
analyses indicated that MGAs were likely to be cost neutral
or cost saving in most settings (US, UK, Canada, Ireland,
and Singapore for Oncotype DX, France for Mamma-
Print); the only exception was the analysis by Kondo et al.
(2011), which reported that Oncotype DX increased costs
but was highly cost-effective in Japan.
Assay accuracy has a large effect on cost-effectiveness,
since incorrect allocation to low risk groups increases the
risk of distant recurrence as a result of under treatment.
Furthermore, incorrect allocation to high risk reduces QoL
and increases costs due to overtreatment with chemotherapy
[43]. MGAs with significant clinical data to support their use
were shown in health economic evaluations, to improve
outcomes both by assigning patients to chemotherapy who
would not have previously received treatment, and by
sparing patients from the adverse effects of chemotherapy
who are unlikely to benefit. Assays were most likely to be
cost-effective in settings where a high proportion of early-
stage breast cancer patients received chemotherapy and
where chemotherapy was costly. In these settings, assays
benefit patients by reducing the number of adverse events
associated with chemotherapy and payers by reducing the
cost of chemotherapy and associated care. Analyses showed
that the cost-effectiveness of MGAs was sensitive to the risk
profile of the population. If few patients are classified as
being at low risk of distant recurrence, assay costs are not
offset by reduced chemotherapy. Still, the literature supports
the cost-effectiveness of MGAs in both LN- and LN?
patients. Published studies examined cost-effectiveness in
Asia, Europe, and North America, indicating that clinical
and cost benefits may be seen in a diverse range of healthcare
settings worldwide.
Therapy allocation guided by either conventional
approaches or Oncotype DX was based on real-life data in
five of the published analyses [26, 31, 32, 34, 37]. This
highlights a limitation of studies on Oncotype DX and
MammaPrint that assign therapy directly from validation
studies (a feature of evaluations comparing the two tests).
In general, studies that assumed chemotherapy prescription
rates produced more positive estimates of cost-effective-
ness (often being cost saving) than those who relied on
real-life data. The exception was the US evaluation in
2011, which showed Oncotype DX testing to be dominant
to decision making based on NCCN guidelines [32]. The
NSABP B-20 study provided data in ER?, LN- patients
and the SWOG 8814 trial provided data in ER?, LN?
patients both demonstrate the prediction of chemotherapy
benefit provided by Oncotype DX [9, 10]. The clinical
validity of Oncotype DX as both a prognostic indicator
and a test predictive of likely chemotherapy benefit is
supported by an evidence base of consistent results from
multiple studies [6, 9, 10, 54, 55]. The evidence supporting
other MGAs are not currently as strong [16].
The studies identified in this review were generally of
high quality, as assessed by the QHES instrument. It should
be acknowledged, however, that a general instrument such
as QHES might have shortcomings for the assessment of
cost-effectiveness analyses (Appendix). The development
of a bespoke checklist focused on cost-effectiveness eval-
uation of diagnostic tests may be a valuable avenue of
future research.
MGAs have the potential to help physicians make more
informed treatment decisions by identifying patients at
high risk of distant recurrence and patients who are likely
to benefit from adjuvant chemotherapy. Similarly, identi-
fying patients at low risk of distant recurrence who can be
spared chemotherapy treatment has notable benefits,
including avoidance of associated adverse events both in
the short-term (captured in all models) and long-term
(captured in one study). This review finds a consistent body
of evidence supporting the cost-effectiveness of Oncotype
DX in informing chemotherapy treatment decisions
regardless of local cost and local clinical practice.
In particular, for patients with ER? early-stage breast
cancer, the benefits negate the acquisition costs of Onco-
type DX and its use in these patients is encouraged. The
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literature suggests that MammaPrint is also likely to be
cost-effective in this patient population. The body of evi-
dence, however, is not as extensive and before encouraging
its general use further research is needed to understand the
influence of local treatment practices and to what extent
this test predicts chemotherapy benefit. Future studies
investigating head-to-head comparisons of MGAs would
provide valuable insights into how these tests influence
adjuvant therapy decision making, and would provide
valuable data for future economic evaluations on the rel-
ative merits of tests in clinical practice in the years ahead.
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Appendix
Congress databases
The congress databases searched were: San Antonio Breast
Cancer Symposium (SABC), American Society of Clinical
Oncology (ASCO), European Breast Cancer Conference
(EBCC), St. Gallen Oncology Conference, European
Society for Medical Oncology (ESMO), European Cancer
Organisation (ECCO), and International Society for Phar-
macoeconomics and Outcomes Research (ISPOR).
Evaluation of study quality
The literature search identified 17 published manuscripts
that were underwent quality assessment using the QHES
instrument. Of these, 11 compared Oncotype DX with
current practice, four evaluated MammaPrint versus cur-
rent practice, and two evaluated Oncotype DX versus
MammaPrint. Overall, the quality of the identified analyses
was high. The mean score for the studies comparing MGAs
with current practice were both 86/100 for the Oncotype
DX and MammaPrint assays (Fig. 2). The most common
area where studies did not meet QHES criterion was
explicit discussion of bias. A number of analyses also
failed to fully describe the model constructed and the
assumptions used. These shortcomings, however, were
relatively minor and only five studies score \80/100.
The quality of the two studies comparing Oncotype
DX and MammaPrint was lower than those comparing
with usual care, scoring 66 and 72. These two studies
received lower ratings primarily as a result of the data
sources used to determine the treatment effects. One study
used randomized controlled trial evidence, but not from a
head-to-head study of the two interventions, and the other
used evidence from small retrospective studies, some of
which was used to inform creation of the MammaPrint test.
Moreover, chemotherapy allocation in high- and low-risk
patient groups was based on assumption. These studies also
received low scores as a result of limited sensitivity anal-
yses and lack of transparency, as very limited information
on the outcomes and drivers of outcomes was given.
Limitations of the QHES instrument
The studies identified in this review were generally of high
quality, as assessed by the QHES instrument. It should be
acknowledged, however, that a general instrument such as
QHES might have shortcomings for the assessment of cost-
effectiveness analyses on diagnostic tests (or screening
studies). For example, the evaluations included in this
review generally followed a 2-step approach, with models
designed to first evaluate therapy allocation, and second to
simulate long-term outcomes. Both steps influence out-
comes, and a general checklist might not be sensitive to
differences between evaluations. The use of local decision
impact study data versus assumptions from a validation
study in step 1 is one example, particularly when the
clinical data underpinning the second step of the analysis is
sound. Moreover, the use of the ‘‘best available source’’
data (a criterion of the QHES) does not pick up on the
relative merits of using, for example, randomized con-
trolled trial data versus meta-analysis data versus
assumption or investigator opinion, so long as, it represents
the ‘‘best available’’ data. One additional point is that the
QHES checklist does not address limitations in the mod-
eling approach. Clearly, this may be difficult to achieve as
part of a general checklist, but it would be a valuable tool
for estimating the influence of the above points on the
Breast Cancer Res Treat (2013) 139:621–637 635
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overall quality of cost-effectiveness modeling evaluation.
The development of a bespoke checklist focused on cost-
effectiveness evaluation of diagnostic tests may be a
valuable avenue of future research.
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